

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

ANNOUNCEMENT

POLL RESULTS OF THE 2021 FIRST EXTRAORDINARY GENERAL MEETING HELD ON 25 JUNE 2021

References are made to the notice and the circulars (the “**Circulars**”) of 2021 first extraordinary general meeting (the “**EGM**”) dated 28 May 2021 of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circulars.

POLL RESULTS OF THE EGM

The EGM was held at Conference Room, 4/F, Administration Building, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang'an County, Dongguan, Guangdong Province, the PRC at 10:00 a.m. on Friday, 25 June 2021. The EGM was legally and effectively held in accordance with the Company Law of the PRC and other relevant laws and regulations of the PRC, the Listing Rules and the Articles of Association.

As at the date of the EGM, the total number of issued shares of the Company was 879,967,700 Shares (comprising 226,200,000 Domestic Shares and 653,767,700 H Shares), entitling the holders thereof to attend the EGM and vote for or against or abstain from voting on the resolutions proposed at the EGM (saved as stated below).

Shareholders attending the EGM, either in person or by proxy, held an aggregate of 135,201,477 Shares with voting rights, representing approximately 15.364368% of the total number of the issued Shares with voting rights.

Guangdong HEC Technology Holding Co., Ltd.* (廣東東陽光科技控股股份有限公司), a company which holds approximately 53.89% equity interest in the Company as at the date of the EGM, (i) is deemed to have a material interest in the Revised Non-Competition Agreements, and is therefore required to abstain from voting on the resolution in relation to the Revised Non-Competition Agreements and the transactions contemplated thereunder (the “**Resolution 1**”); (ii) is deemed to have a material interest in the Purchase Transactions (including the annual caps) and Clarithromycin and Azithromycin Purchase Transaction, and is therefore required to abstain from voting on the resolution in relation to the Purchase Transactions (including the annual caps) and Clarithromycin and Azithromycin Purchase Transaction (the “**Resolution 2**”); and (iii) is deemed to have a material interest in the Entrusted Transactions (including the annual caps), and is therefore required to abstain from voting on the resolution in relation to the Entrusted Transactions (including the annual caps) (the “**Resolution 3**”, together with the Resolution 1 and the Resolution 2, the “**Resolutions**”). Save as disclosed in this announcement, no Shareholder was required by the Listing Rules to abstain from voting on any of the resolutions proposed at the EGM. Therefore, an aggregate of 405,752,500 Shares (representing approximately 46.11% of the total number of the issued Shares of the Company) entitle the Independent Shareholders to attend the EGM and vote on the Resolutions.

Saved as disclosed above, there was no Share entitling its holder to attend the EGM and abstain from voting in favour of any of the proposed resolutions under Rule 13.40 of the Listing Rules. No Shareholder has stated the intention in the Circulars to vote against or to abstain from voting on any of the proposed resolutions. All the proposed resolutions were voted by way of poll. Computershare Hong Kong Investor Services Limited, the H share registrar of the Company, acted as the scrutineer for vote-taking at the EGM. Two shareholder representatives and one supervisor of the Company also acted as the scrutineers for the vote-taking and vote-tabulation.

Poll Results of the EGM

The poll results of the EGM are as follows:

ORDINARY RESOLUTIONS		NUMBER OF VOTES AND PERCENTAGE OF TOTAL NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the transactions under the Revised Non-Competition Agreements.	134,784,277 (99.691571%)	0 (0.000000%)	417,000 (0.308429%)
2.	To consider and approve the transactions under the Purchase Transactions (including the annual caps) and Clarithromycin and Azithromycin Purchase Transaction.	135,201,477 (100.000000%)	0 (0.000000%)	0 (0.000000%)
3.	To consider and approve the transactions under the Entrusted Transactions (including the annual caps).	135,201,477 (100.000000%)	0 (0.000000%)	0 (0.000000%)

As more than half of the votes from the Shareholders (including their proxies) attending the EGM were cast in favour of the resolutions numbered 1 to 3, the Resolutions were duly passed as ordinary resolutions.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC
25 June 2021

As of the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yanguai and Mr. LI Shuang as executive Directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive Directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.

* *For identification purposes only*